Lipella Pharmaceuticals Inc
lipella.comWhat Do They Do?
Develops reformulated medicines from existing generic drugs for patients with bladder and oral conditions, including hemorrhagic cystitis and oral lichen planus.
10-K for FY2024, filed Mar 28, 2025We are a clinical-stage biotechnology company that was incorporated under the laws of the State of Delaware in February 2005. We are…View ↗
Consistent with our strategy, we are currently addressing two indications via development of our product candidates, which we have…View ↗
LP-10 is the development name of our reformulation of tacrolimus (an approved generic active agent) specifically optimized for topical…View ↗
LP-310 is the development name of our oral, liposomal formulation of tacrolimus (the same approved generic active agent in LP-10)…View ↗
How Do They Make Money?
It earns fixed fees for project deliverables or hourly charges plus project costs from third-party customers. It also receives research grants, primarily from the NIH, as grant-funded work is performed.
10-K for FY2024, filed Mar 28, 2025Under a fixed-fee contract, the Company charges a fixed agreed upon amount for a deliverable. Fixed-fee contracts have fixed deliverables…View ↗
Under a time and materials contract, the Company charges customers an hourly rate plus reimbursement for other project specific costs. The…View ↗
The Company has concluded its government grants are not within the scope of Topic 606, as government entities do not meet the definition of…View ↗
$536.4K
-
10-K for FY2024, filed Mar 28, 2025
$536.4K ↗
Who Are Their Customers?
Third-party customers engage the company for fixed-fee or time-and-materials projects. Government and nonprofit sources, primarily NIH, fund qualified research and development activities through grants.
10-K for FY2024, filed Mar 28, 2025The Company’s contract revenue consists primarily of amounts earned under contracts with third-party customers and reimbursed expenses…View ↗
Under a fixed-fee contract, the Company charges a fixed agreed upon amount for a deliverable. Fixed-fee contracts have fixed deliverables…View ↗
Under a time and materials contract, the Company charges customers an hourly rate plus reimbursement for other project specific costs. The…View ↗
The Company has concluded its government grants are not within the scope of Topic 606, as government entities do not meet the definition of…View ↗
Do Revenues Turn Into Profits?
No. It lost $5M in FY2024.
10-K for FY2024, filed Mar 28, 2025
How Are They Changing?
- Net income
-
Sources
10-Q for Q3 FY2025, filed Nov 14, 2025
−$1.3MView ↗
- ▼ −13% (Loss)
- vs −$1.4M in Q3 FY2024
-
Jul 15, 2026
Filed for Chapter 11 and received approval to sell substantially all assets
The company agreed to sell substantially all assets to XRAIY; the court approved the sale.
Sources
8-K, filed Jul 15, 2026
On March 30, 2026, Lipella Pharmaceuticals Inc. (the “Company”) filed a voluntary petition for relief under chapter 11 of title 11 of the…View ↗
-
Jun 20, 2025
Nasdaq decided to delist the company's common stock
Trading in the common stock was suspended, and it was quoted on the Pink Market.
Sources
8-K, filed Jun 20, 2025
On June 20, 2025, Lipella Pharmaceuticals Inc., a Delaware corporation (the “Company”, “we”, “us” or “our”), received a letter (the…View ↗
Loading...
